

Special Issue

Immunization of Immunosuppressed Patients

Message from the Guest Editors

Mass vaccination campaigns have largely mitigated the healthcare burden of COVID-19, and booster vaccinations are being regularly updated. Nevertheless, vaccine response and efficacy remain suboptimal, mainly in those who need care the most, i.e., immunocompromised patients. In this Special Issue, we will analyze the effectiveness of different COVID-19 vaccine formulations across different cohorts of immunocompromised patients. Cohorts will range from oncohematological patients to solid organ transplant recipients to patients with autoimmune disorders. The Special Issue welcomes original research studies on novel vaccine approaches (e.g., mucosal delivery or novel adjuvants) and epidemiological studies or rigorous systematic reviews on vaccine efficacy in particular cohorts of immunocompromised patients. We look forward to receiving your contributions.

Guest Editors

Dr. Massimo Franchini

Department of Hematology and Transfusion Medicine, Carlo Poma Hospital, 46100 Mantua, Italy

Dr. Daniele Focosi

North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy

Deadline for manuscript submissions

30 June 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/219379

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).